Arcadia Biosciences, Inc. (RKDA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 89/100 (CRITICAL), 5.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.47% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
- Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights
- Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights
- Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis. — Acta Derm Venereol 2026 Jun 10 PMID 42272192
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Arcadia Biosciences, Inc..
Full RKDA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.